XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. - Wikidata - awgldk - TriplyDB

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.

http://www.wikidata.org/entity/Q34630237

about

Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials Role of targeted therapy in metastatic colorectal cancer Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Oral drugs in the treatment of metastatic colorectal cancer.Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised co Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis.Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases.Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN)S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab.Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)Primary tumor location as a prognostic factor in metastatic colorectal cancer.A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard)Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis.Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report.Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer.Management of a locally advanced rectal cancer in a patient who declined surgery.Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer.Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer.Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer.Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions.Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis.Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer.Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies.Role of capecitabine in treating metastatic colorectal cancer in Chinese patients.A postauthorization survey to document the therapeutic management of oxaliplatin as a first-line chemotherapy regimen in South Africa in patients with metastatic colorectal cancer.Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status.Therapeutic strategies for hepatic metastasis of colorectal cancer: overview.Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept.

P2860

Q26862559-EDD840F3-D2BB-43EB-8057-1249F67AB65B Q27028095-6E531F52-C8A1-474A-A979-6E461A2D0543 Q28068817-E944570D-7B47-40AE-87ED-93F5A4DD935F Q30249335-D64CABF9-CF9C-4433-A48C-0E7FF5B966C0 Q30251387-30B6BFF8-BE0D-4A61-8382-5111C79A2E38 Q30316930-2263CC42-244C-4110-8295-115B6018F3DF Q33398998-61EDEA46-C789-4A31-95B9-A72B43BB5B52 Q33442681-3872485D-6C35-4A8C-BE00-9D47E4E31296 Q33602255-13ED356F-F222-4FDA-98AB-38F2A8A07FCF Q33720942-1290BECE-74DC-44AA-834C-DEDCAC5DA94B Q33868520-5775B113-BDE5-45C1-A36D-65D64C492A5A Q34897322-A9F93670-F72A-42E6-B4A4-F08AD5207408 Q35043817-A138548E-9440-40E1-98F2-BBEF586451EC Q35746635-A0CF30DF-1CF2-4E4F-88B4-C5FBA9E8A6CF Q35807573-A57C186E-FA2C-433B-BAF0-F3CACABEB208 Q35938926-2E60FCAA-3A34-4804-B1EF-FF1E02656132 Q36047405-471D3264-4063-4F1E-A056-F58A09E1DBB8 Q36102819-D1AE0D5C-EC95-4250-8C37-4032331F24C1 Q36112303-50946C45-B26C-46B4-9E6F-8277110B02DA Q36303226-7CCC0AE8-2A94-499D-81C9-F221F1B7C4DC Q36338494-DEE5C1F6-C8D1-4C0B-8E3D-91B809ED2364 Q36385665-A929D05A-B10E-43D6-A975-5C699DC4913E Q36498946-EE9D9D21-151C-44F9-8F17-6B9982B975B4 Q36598736-78759DF1-DE72-4A72-B98F-CA8D5D709BA0 Q36613847-BC622DDB-045A-465B-B57B-3E2BF69DC982 Q36706109-3E2658D7-55E8-4A03-B6D7-2B9C03B53105 Q36778075-04357192-6ECC-403C-9634-D143D4AF25F4 Q36813649-D173DD7A-125A-48FA-8641-7BC38B0529B7 Q37166391-D754A998-4D4E-4197-9DED-9BED480628E3 Q37272489-47F57A3D-DA93-4A68-BECE-EC1C18C4D9D4 Q37458009-68E68F92-23E3-4ABC-A463-040513685342 Q37530472-40D84396-2904-4093-80F2-E8FA7539A237 Q37560960-D4755E11-B42C-498C-8F72-95DF3162B6CA Q37632167-ED905CAC-37DA-4B41-B884-3587826B8D8A Q37692395-C0CF6910-C762-4AF7-B1B2-93789398B33F Q37730640-DEAB7170-2C00-4F19-927A-30CC0F48D708 Q37975508-8851B65D-2061-4EED-880F-43CD58377640 Q38019380-5683DD37-D1DA-4BC6-88EA-F79616CEEAE7 Q38216009-9DF3359B-4F79-487D-9BEA-01C080A056E3 Q38241190-76CD0130-E52B-4FF5-93F3-D858A7362E38

P2860

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.

http://www.wikidata.org/entity/Q34630237

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

XELOX vs FOLFOX-4 as first-lin ...... ncer: NO16966 updated results.

@ast

XELOX vs FOLFOX-4 as first-lin ...... ncer: NO16966 updated results.

@en

XELOX vs FOLFOX-4 as first-lin ...... ncer: NO16966 updated results.

@nl

type

label

XELOX vs FOLFOX-4 as first-lin ...... ncer: NO16966 updated results.

@ast

XELOX vs FOLFOX-4 as first-lin ...... ncer: NO16966 updated results.

@en

XELOX vs FOLFOX-4 as first-lin ...... ncer: NO16966 updated results.

@nl

prefLabel

XELOX vs FOLFOX-4 as first-lin ...... ncer: NO16966 updated results.

@ast

XELOX vs FOLFOX-4 as first-lin ...... ncer: NO16966 updated results.

@en

XELOX vs FOLFOX-4 as first-lin ...... ncer: NO16966 updated results.

@nl

P1433

Q34630237-8C514F73-EA6F-403F-ACD8-FC67B441FA69

P1476

Q34630237-AEE15312-AC67-4610-9208-750F2232A254

P2093

Q34630237-1029DD1A-70E6-4DD5-B4DA-C80BAE6AEB8F

Q34630237-377E77D6-6163-4039-8C04-33FAF5DC8362

Q34630237-48129D4B-E7BA-4584-A211-AE2E4D6B651D

Q34630237-5924B365-FC2B-4E3F-B878-A8855878FA50

Q34630237-7BC6FFB6-2955-4232-A761-229326F3E1A8

Q34630237-BAE0A538-285B-4FAC-BF57-DF5717654D97

Q34630237-D100FC25-1B11-4468-89EA-A78FDFC61BAA

Q34630237-EE4D71A0-99AC-4B44-AD12-802A4BDF948E

P2860

Q34630237-06A59F86-6BCE-4E8E-967D-C3F01FB85DCE

Q34630237-1303BCC5-D9CD-47EC-83A7-791BCC5D14DA

Q34630237-3D3A579B-2872-451C-B75F-A2F124E23EDA

Q34630237-406C7BF6-006E-49DB-8B25-0E4BE72C28A0

Q34630237-5C002306-A023-4102-BD6A-55138F532357

Q34630237-971B2C41-103F-4C8B-92AB-295630AF67DD

Q34630237-9D774E36-DD46-419A-952A-CE3B41458A01

Q34630237-C7EDD608-901C-40CB-91DC-1BADB575BC2D

Q34630237-CDDEF24D-20AA-40C3-BD03-6E642E4F8903

Q34630237-DDF4899A-313A-4C83-B05A-D39132513A4C

P2888

Q34630237-8A7A0C83-4371-4F79-9461-913E0572531A

P304

Q34630237-04515C0E-75FF-4571-89E0-10FE0AA08B19

P31

Q34630237-828297A7-4A25-478D-9F2C-E2E33BE35E80

P356

Q34630237-B443ED18-BD07-4319-99FE-33E8E49DF452

P407

Q34630237-E61F389A-B92B-4AD8-A3AF-89E16E37B891

P433

Q34630237-CC35B9A4-471F-4445-AE78-47E5BACEACE2

P478

Q34630237-78DADE7D-370B-4E6B-AEA7-73E5782D5A56

P50

Q34630237-95BA7979-CE58-4911-BE26-AED80745C018

Q34630237-E8C60C3D-02C7-40C9-81ED-EDBAF56D40E3

P577

Q34630237-EA812818-0465-4407-882C-3DF4DE6D502B

P5875

Q34630237-E22DEEFA-5D94-43D4-8A57-98F28C39A654

P6179

Q34630237-CE6D48F0-4DD9-47EB-BA75-75188FE4011F

P698

Q34630237-5E751DCE-B9F7-4AB3-A2E8-D16CF52C6233

P921

Q34630237-BDF2D3BF-529E-4289-8AB3-DB0D53000A1A

P932

Q34630237-5D9ABD47-5BD3-461A-AC53-93E059D9FE08

P356

P1433

British Journal of Cancer

P1476

XELOX vs FOLFOX-4 as first-lin ...... ancer: NO16966 updated results

@en

P2093

A Figer

http://www.w3.org/2001/XMLSchema#string

F Gilberg

http://www.w3.org/2001/XMLSchema#string

J Cassidy

http://www.w3.org/2001/XMLSchema#string

K Rittweger

http://www.w3.org/2001/XMLSchema#string

R Wong

http://www.w3.org/2001/XMLSchema#string

S Clarke

http://www.w3.org/2001/XMLSchema#string

S Koski

http://www.w3.org/2001/XMLSchema#string

W Scheithauer

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Capecitabine as adjuvant treatment for stage III colon cancer.

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-

Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.

P2888

P304

58-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2011.201

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Leonard B. Saltz

Eduardo Díaz-Rubio

P577

2011-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51219682

http://www.w3.org/2001/XMLSchema#string

P6179

1017729876

http://www.w3.org/2001/XMLSchema#string

P698

21673685

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3137415

http://www.w3.org/2001/XMLSchema#string